ABERNETHY MATT
Chief Financial Officer
ABERNETHY MATT has filed 4 SEC Form 4 filings (14 transaction rows) across 1 company, with disclosures dating back to 2026. 4 of those filings fall inside the rolling window. Most recent filing: Sep 15, 2026.
On the most recent filing, ABERNETHY MATT is listed as Chief Financial Officer at NEUROCRINE BIOSCIENCES INC. Inside the rolling window, ABERNETHY MATT reported no open-market purchases and 1 open-market sale totaling $363K in NBIX.
Companies traded
Other insiders at NBIX
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$363K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has ABERNETHY MATT made?
ABERNETHY MATT has filed 4 SEC Form 4 filings (14 transaction rows) across 1 company since 2026.
Which companies does ABERNETHY MATT trade?
ABERNETHY MATT has filed SEC Form 4 disclosures for 1 company, including NBIX.
When was ABERNETHY MATT's most recent SEC Form 4 filing?
ABERNETHY MATT's most recent SEC Form 4 filing on Tracefour is dated Sep 15, 2026.
What is ABERNETHY MATT's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, ABERNETHY MATT is listed as Chief Financial Officer.
What is ABERNETHY MATT's total buy and sell value in the current window?
Inside the rolling retention window, ABERNETHY MATT bought $0 and sold $363K based on SEC Form 4 filings.
What was ABERNETHY MATT's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 2,311 NBIX shares on 2026-09-14, worth $363K, per SEC Form 4 filings.